• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动态 3'-脱氧-3'-[F]氟代胸苷 ([F]FLT) PET 采集需要多长时间才能进行稳健的乳腺癌动力学分析?

How Long of a Dynamic 3'-Deoxy-3'-[F]fluorothymidine ([F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer?

机构信息

Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, 395 W. 12th Avenue, Room 430, Columbus, OH, 43210-1228, USA.

Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.

出版信息

Mol Imaging Biol. 2019 Apr;21(2):382-390. doi: 10.1007/s11307-018-1231-x.

DOI:10.1007/s11307-018-1231-x
PMID:29987617
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7201384/
Abstract

PURPOSE

To quantitatively evaluate the minimally required scanning time of 3'-deoxy-3'-[F]fluorothymidine ([F]FLT) positron emission tomography (PET) dynamic acquisition for accurate kinetic assessment of the proliferation in breast cancer tumors.

PROCEDURES

Within a therapeutic intervention trial, 26 breast tumors of 8 breast cancer patients were analyzed from 30-min dynamic [F]FLT-PET acquisitions. PET/CT was acquired on a Gemini TF 64 system (Philips Healthcare) and reconstructed into 26 frames (8 × 15 s, 6 × 30 s, 5 × 1 min, 5 × 2 min, and 2 × 5 min). Maximum activity concentrations (Bq/ml) of volume of interests over tumors and plasma in descending aorta were obtained over time frames. Kinetic parameters were estimated using in-house developed software with the two-tissue three-compartment irreversible model (2TCM) (K, k, k, and K; k = 0) and Patlak model (K) based on different acquisition durations (T) (10, 12, 14, 16, 20, 25, and 30 min, separately). Different linear regression onset time (T) points (1, 2, 3, 4, and 5 min) were applied in Patlak analysis. K of the 30-min data set was taken as the gold standard for comparison. Pearson product-moment correlation coefficient (R) of 0.9 was chosen as a limit for the correlation.

RESULTS

The correlation of kinetic parameters between the gold standard and the abbreviated dynamic data series increased with longer T from 10 to 30 min. k and k using 2TCM and K using Patlak model revealed poor correlations for dynamic PET with T ≤ 14 min (k: R = 0.84, 0.85, 0.86; k: R = 0.67, 0.67, 0.67; K: R = 0.72, 0.78, 0.87 at T = 10, 12, and 14 min, respectively). Excellent correlations were shown for all kinetic parameters when T ≥ 16 min regardless of the kinetic model and T value (R > 0.9).

CONCLUSIONS

This study indicates that a 16-min dynamic PET acquisition appears to be sufficient to provide accurate [F]FLT kinetics to quantitatively assess the proliferation in breast cancer lesions.

摘要

目的

定量评估 3'-脱氧-3'-[F]氟代胸苷([F]FLT)正电子发射断层扫描(PET)动态采集的最小扫描时间,以准确评估乳腺癌肿瘤的增殖情况。

方法

在一项治疗干预试验中,对 8 名乳腺癌患者的 26 个乳腺癌肿瘤进行了分析,这些肿瘤来自于 30 分钟的动态[F]FLT-PET 采集。PET/CT 在 Gemini TF 64 系统(飞利浦医疗保健公司)上采集,并重建为 26 个帧(8×15s、6×30s、5×1min、5×2min 和 2×5min)。通过时间帧获得肿瘤和降主动脉血浆中感兴趣区域的最大放射性浓度(Bq/ml)。使用内部开发的软件,基于不同的采集时间(T)(分别为 10、12、14、16、20、25 和 30 分钟),使用双组织三室不可逆模型(2TCM)(K、k、k 和 K;k=0)和 Patlak 模型(K)估算动力学参数。在 Patlak 分析中,应用了不同的线性回归起始时间(T)点(1、2、3、4 和 5 分钟)。将 30 分钟数据集的 K 作为比较的金标准。选择 Pearson 乘积矩相关系数(R)为 0.9 作为相关的限制。

结果

金标准与缩短的动态数据序列之间的动力学参数相关性随着 T 从 10 分钟增加到 30 分钟而增加。使用 2TCM 的 k 和 k 以及 Patlak 模型的 K 在 T≤14 分钟的动态 PET 中显示出较差的相关性(k:R=0.84、0.85、0.86;k:R=0.67、0.67、0.67;K:R=0.72、0.78、0.87 在 T=10、12 和 14 分钟时)。当 T≥16 分钟时,无论动力学模型和 T 值如何,所有动力学参数均显示出极好的相关性(R>0.9)。

结论

本研究表明,16 分钟的动态 PET 采集似乎足以提供准确的[F]FLT 动力学信息,以定量评估乳腺癌病变的增殖情况。

相似文献

1
How Long of a Dynamic 3'-Deoxy-3'-[F]fluorothymidine ([F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer?动态 3'-脱氧-3'-[F]氟代胸苷 ([F]FLT) PET 采集需要多长时间才能进行稳健的乳腺癌动力学分析?
Mol Imaging Biol. 2019 Apr;21(2):382-390. doi: 10.1007/s11307-018-1231-x.
2
[¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.贝伐单抗治疗下局部晚期乳腺癌患者的[¹⁸F]氟胸苷正电子发射断层扫描:不同肿瘤增殖定量方法的实用性
Rev Esp Med Nucl Imagen Mol. 2014 Sep-Oct;33(5):280-5. doi: 10.1016/j.remn.2014.01.007. Epub 2014 Jul 23.
3
Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.通过3'-氟-3'-脱氧-L-胸腺嘧啶正电子发射断层扫描评估新诊断的高级别胶质瘤患者的胶质瘤增殖情况。
Clin Cancer Res. 2008 Apr 1;14(7):2049-55. doi: 10.1158/1078-0432.CCR-07-1553.
4
Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.用于小鼠皮下肿瘤模型定量细胞增殖成像的3'-脱氧-3'-¹⁸F-氟胸腺嘧啶核苷的动力学建模
J Nucl Med. 2008 Dec;49(12):2057-66. doi: 10.2967/jnumed.108.053215. Epub 2008 Nov 7.
5
In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.3'-脱氧-3'-[(18)F]氟胸苷([(18)F]FLT)作为人体增殖显像示踪剂的体内验证:正电子发射断层扫描检测的[(18)F]FLT摄取与人类肺肿瘤中Ki-67免疫组织化学及流式细胞术的相关性
Clin Cancer Res. 2002 Nov;8(11):3315-23.
6
Feasibility of using abbreviated scan protocols with population-based input functions for accurate kinetic modeling of [F]-FDG datasets from a long axial FOV PET scanner.基于群体输入函数的简化扫描方案用于长轴向视野 PET 扫描仪 [F]-FDG 数据集准确动力学建模的可行性。
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):257-265. doi: 10.1007/s00259-022-05983-7. Epub 2022 Oct 4.
7
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.利用18F-FLT PET成像检测脑肿瘤增殖:与18F-FDG的比较。
J Nucl Med. 2005 Jun;46(6):945-52.
8
Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.通过[18F]氟代胸苷正电子发射断层扫描成像对乳腺癌患者肿瘤组织和正常组织中细胞增殖进行定量分析:分析方法的评估
Cancer Res. 2005 Nov 1;65(21):10104-12. doi: 10.1158/0008-5472.CAN-04-4297.
9
Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.在高级别胶质瘤基因工程小鼠模型中,使用3'-脱氧-3'-18F-氟胸腺嘧啶核苷对肿瘤增殖进行动态小动物PET成像。
J Nucl Med. 2008 Mar;49(3):422-9. doi: 10.2967/jnumed.107.047092. Epub 2008 Feb 20.
10
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.3'-脱氧-3'-¹⁸F-氟胸苷PET用于评估乳腺癌对新辅助化疗早期反应的II期研究:来自ACRIN 6688的结果
J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.

引用本文的文献

1
Exploring the role of tumor to background parenchymal ratio of the [18F]FLT PET/CT measures in determining response to neoadjuvant chemotherapy in breast cancer: a multicenter study.探索[18F]氟代胸苷正电子发射断层显像/计算机断层扫描([18F]FLT PET/CT)测量的肿瘤与背景实质比在确定乳腺癌新辅助化疗反应中的作用:一项多中心研究。
BMC Cancer. 2025 Jul 3;25(1):1139. doi: 10.1186/s12885-025-14534-w.
2
Technical note: Partitioning of gated single photon emission computed tomography raw data for protocols optimization.技术说明:门控单光子发射计算机断层扫描原始数据的分区,用于协议优化。
J Appl Clin Med Phys. 2022 Mar;23(3):e13508. doi: 10.1002/acm2.13508. Epub 2021 Dec 17.
3
Dual time point [F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues.双时间点[F]氟代胸苷正电子发射断层扫描用于区分增殖组织与非增殖组织。
EJNMMI Res. 2019 Dec 12;9(1):109. doi: 10.1186/s13550-019-0579-5.

本文引用的文献

1
Parametric Method Performance for Dynamic 3'-Deoxy-3'-F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.动态 3'-脱氧-3'-F-氟代胸苷 PET/CT 参数法性能在表皮生长因子受体突变型非小细胞肺癌患者治疗前后。
J Nucl Med. 2017 Jun;58(6):920-925. doi: 10.2967/jnumed.116.178418. Epub 2016 Nov 10.
2
A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.一项关于[(18)F]氟代胸苷正电子发射断层扫描([(18)F]FLT-PET)摄取作为癌症患者治疗反应指标的系统评价。
Eur J Cancer. 2016 Mar;55:81-97. doi: 10.1016/j.ejca.2015.11.018. Epub 2016 Jan 25.
3
Quantification of 18F-Fluoride Kinetics: Evaluation of Simplified Methods.18F-氟化物动力学定量:简化方法评估。
J Nucl Med. 2014 Jul;55(7):1122-7. doi: 10.2967/jnumed.113.135269. Epub 2014 May 27.
4
Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity.¹⁸F-氟-3-脱氧-3-L-氟胸苷PET数据的参数成像以研究肿瘤异质性。
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1781-92. doi: 10.1007/s00259-014-2757-z. Epub 2014 Apr 5.
5
Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.复发性和转移性乳腺癌的PET、PET/CT、PET/MRI:氟代脱氧葡萄糖及新生物标志物
Q J Nucl Med Mol Imaging. 2013 Dec;57(4):352-66.
6
Molecular imaging for monitoring treatment response in breast cancer patients.用于监测乳腺癌患者治疗反应的分子成像。
Eur J Pharmacol. 2013 Oct 5;717(1-3):2-11. doi: 10.1016/j.ejphar.2013.01.079. Epub 2013 Mar 30.
7
Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT.使用小动物PET及[¹⁸F]FDG和[¹⁸F]FLT对源自PyMT肿瘤建立的免疫活性小鼠乳腺癌模型进行比较功能评估。
Am J Nucl Med Mol Imaging. 2012;2(1):88-98. Epub 2011 Dec 15.
8
Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.动态 FDG-PET 和 PET/CT 研究(dPET/CT)的定量方法在肿瘤患者评估中的应用。
Cancer Imaging. 2012 Sep 28;12(1):283-9. doi: 10.1102/1470-7330.2012.0033.
9
Impact of iterative reconstruction on CNR and SNR in dynamic myocardial perfusion imaging in an animal model.迭代重建对动物模型动态心肌灌注成像中 CNR 和 SNR 的影响。
Eur Radiol. 2012 Dec;22(12):2654-61. doi: 10.1007/s00330-012-2525-z. Epub 2012 Jul 3.
10
Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis.Ki-67 免疫组化与癌症患者 18F-氟脱氧胸苷摄取的相关性:系统评价和荟萃分析。
Eur J Cancer. 2012 Dec;48(18):3499-513. doi: 10.1016/j.ejca.2012.05.001. Epub 2012 May 31.